TickerFacts.

Company research / QGEN

Qiagen N.V. (QGEN)

Build a valuation ↗↓ Download CSV

SEC name QIAGEN N.V. · CIK 0001015820 · NYSE · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Qiagen N.V. reported revenue of $2.09B. Revenue grew 5.7% from the prior annual period.

Key ratios (year ended 2025-12-31)

62.2%
Gross margin
22.3%
Operating margin
20.3%
Net margin
11.2%
Return on year-end equity
5.7%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 6-K (current report) · 2026-09-09

Headquarters locality: Venlo · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

Period ended2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$2.09B$1.98B$1.97B$2.14B$2.25B$1.87B$1.53B$1.50B$1.42B$1.34B
Cost of Revenue$790.50M$1.01B$731.62M$756.96M$800.84M$637.63M$521.16M$500.89M$494.98M$493.34M
Gross Profit$1.30B$967.35M$1.23B$1.38B$1.45B$1.23B$1.01B$1.00B$922.56M$844.65M
R&D Expense$187.52M$193.49M$198.51M$189.86M$189.96M$149.07M$157.45M$161.85M$154.08M$149.84M
Operating Income$465.85M$97.71M$409.94M$531.46M$630.08M$386.43M-$26.14M$266.58M$153.42M$98.83M
Depreciation & Amortization$193.75M$203.27M$205.34M$208.40M$214.93M$205.01M$231.46M$206.44M$216.45M$213.06M
EBITDA$659.60M$300.98M$615.27M$739.86M$845.01M$591.45M$205.32M$473.02M$369.87M$311.88M
Net Income$424.88M$83.59M$341.30M$423.21M$512.60M$359.19M-$41.45M$190.38M$40.39M$80.40M
EPS (Diluted)$1.94$0.37$1.48$1.84$2.21$1.53-$0.18$0.82$0.17$0.34
Total Assets$6.28B$5.69B$6.12B$6.29B$6.15B$5.87B$5.24B$5.75B$5.04B$4.31B
Long-Term Debt$1.65B$1.39B$1.51B$1.86B$1.94B$1.92B$1.71B$2.17B$1.76B$1.07B
Shareholders' Equity$3.78B$3.57B$3.81B$3.47B$3.10B$2.80B$2.54B$2.63Bn/a$2.61B
Cash & Equivalents$839.00M$663.55M$668.08M$730.67M$880.52M$597.98M$623.65M$1.16B$657.71M$439.18M
Operating Cash Flow$654.33M$673.55M$459.45M$715.26M$639.00M$457.81M$330.84M$359.50M$286.78M$341.60M
Capital Expenditures$201.05M$167.17M$149.71M$129.22M$189.90M$132.79M$117.95M$109.77M$90.08M$74.54M
Free Cash Flow$453.28M$506.38M$309.75M$586.04M$449.10M$325.02M$212.89M$249.72M$196.70M$267.07M
Share Repurchases$280.09M$292.10M$0$0$99.99M$63.99M$74.45M$104.69M$60.97M$0
Dividends Paid$54.24M$0$0n/an/an/an/an/an/an/a
Dividends Per Share$0.25n/an/an/an/an/an/an/an/an/a
Weighted Average Diluted Shares218.88M224.72M230.62M230.14M232.03M234.21M226.78M233.46M233.01M238.99M
EPS (Basic)$1.96$0.38$1.50$1.86$2.25$1.57-$0.18$0.84$0.18$0.34

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView